title: Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials.
abstract: BACKGROUND
  Impaired renal function is a major complication of type 2 diabetes mellitus (T2DM). Mild renal impairment is present in 38% of patients with T2DM and may impact choice of antihyperglycemic agent. Sulfonylureas and dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used to treat hyperglycemia in patients with T2DM and renal impairment. Although in general sulfonylurea use is associated with an increased risk of hypoglycemia and weight gain, while DPP-4 inhibitor use is associated with a low risk of hypoglycemia, and is weight neutral, the relative efficacy and tolerability of these agents in patients with mild renal impairment has not been evaluated.
  
  
  METHODS
  In a post hoc analysis, data from 1,211 subjects with T2DM and mild renal impairment (estimated glomerular filtration rates of 60 to <90 mL/min/1.73 m(2)), who completed 25 or 30 weeks of one of three double-blind clinical trials comparing the DPP-4 inhibitor sitagliptin 100 mg/day with sulfonylureas in titrated doses, were pooled. The analysis compared change from baseline in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), body weight, incidence of symptomatic hypoglycemia and the percentages of subjects meeting a composite endpoint of HbA1c decrease >0.5% without symptomatic hypoglycemia or body weight gain between sitagliptin and sulfonylurea treatment groups.
  
  
  RESULTS
  HbA1c and FPG decreased similarly with sitagliptin or sulfonylurea. A lower incidence of hypoglycemia was observed with sitagliptin. Body weight decreased with sitagliptin but increased with sulfonylurea. A greater percentage of subjects treated with sitagliptin (41.1%) than treated with sulfonylurea (16.9%) achieved the composite endpoint of >0.5% HbA1c reduction with no symptomatic hypoglycemia or body weight gain.
  
  
  CONCLUSIONS
  In this analysis of subjects with T2DM and mild renal impairment, treatment with sitagliptin provided glycemic efficacy similar to sulfonylurea, with less hypoglycemia and with body weight loss compared to body weight gain seen with sulfonylurea.
  
  
  BACKGROUND
  ClinicalTrials.gov #NCT00482079, #NCT00094770, #NCT00701090.
authors: Merck & Co., Inc., Whitehouse Station, NJ, USA, elizabeth.ommen@merck.com.
authors: Elizabeth S
authors: ES
authors: Ommen
authors: Lei
authors: L
authors: Xu
authors: Edward A
authors: EA
authors: O'Neill
authors: Barry J
authors: BJ
authors: Goldstein
authors: Keith D
authors: KD
authors: Kaufman
authors: Samuel S
authors: SS
authors: Engel
references: Diabetes Obes Metab. 2007 Mar;9(2):194-205
references: 17300595
references: Clin Pharmacol Ther. 2005 Dec;78(6):675-88
references: 16338283
references: Ann Intern Med. 1999 Mar 16;130(6):461-70
references: 10075613
references: Adv Ther. 2013 Jun;30(6):557-76
references: 23797471
references: Exp Clin Endocrinol Diabetes. 1996;104(1):1-9
references: 8750563
references: Curr Diabetes Rev. 2013 May;9(3):195-208
references: 23506375
references: Diabetes Care. 2012 Jun;35(6):1364-79
references: 22517736
references: J Am Soc Nephrol. 2007 Oct;18(10):2749-57
references: 17855641
references: Lancet. 2010 Aug 7;376(9739):419-30
references: 20594588
references: Diabetes Obes Metab. 2013 Jan;15(1):42-54
references: 22862847
references: Diabetes Obes Metab. 2011 Feb;13(2):160-8
references: 21199268
references: Stat Med. 1985 Apr-Jun;4(2):213-26
references: 4023479
references: Am J Kidney Dis. 2013 Apr;61(4):579-87
references: 23352379
references: Endocr Pract. 2013 Nov-Dec;19(6):1025-34
references: 23757605
references: Lancet Diabetes Endocrinol. 2014 May;2(5):369-84
references: 24795251
references: Diabetes Ther. 2013 Jun;4(1):119-45
references: 23700194
references: BMC Res Notes. 2014 Jul 02;7:415
references: 24990184
references: Int J Clin Pract. 2007 Jan;61(1):171-80
references: 17156104
references: Clin Ther. 2009 Nov;31(11):2608-17
references: 20110005
references: J Am Soc Nephrol. 2009 Aug;20(8):1813-21
references: 19443635
references: Clin Pharmacol Ther. 2007 May;81(5):761-7
references: 17392725
references: Am J Kidney Dis. 2008 Apr;51(4 Suppl 2):S21-9
references: 18359404
references: Am J Kidney Dis. 2009 Apr;53(4 Suppl 4):S11-21
references: 19285607
references: Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1027-35
references: 23960029
references: Int J Clin Pract. 2010 Apr;64(5):562-76
references: 20456211
references: Diabetes Care. 2007 Jul;30(7):1862-4
references: 17468348
references: Ann Intern Med. 2009 May 5;150(9):604-12
references: 19414839
references: Kidney Int. 2013 Sep;84(3):622-3
references: 23989362
references: Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
references: 11904577
references: Diabetes Care. 2013 May;36(5):1067-73
references: 23248197
references: N Engl J Med. 2008 Oct 9;359(15):1577-89
references: 18784090